marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2025-Q2
added 08-13-2025
Aethlon Medical Revenue 2011-2025 | AEMD
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:
Revenue = Price * Quantity of products
Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Aethlon Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 574 K | 294 K | 659 K | 650 K | 230 K | 150 K | 392 K | 887 K | 762 K | 1.62 M | 1.23 M | 1.36 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.62 M | 150 K | 734 K |
Quarterly Revenue Aethlon Medical
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.1 K | 281 K | 264 K | - | 625 K | 625 K | - | - | 413 K | 413 K | - | 30 K | - | - | - | - | 74.8 K | - | - | - | - | 392 K | 4.64 K | - | - | - | - | - | 33.4 K | 479 K | 51.3 K | - | 76.3 K | 917 K | 840 K | - | 209 K | 826 K | 617 K | - | 958 K | 958 K | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 958 K | 4.64 K | 414 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Dynatronics Corporation
DYNT
|
27.4 M | $ 0.24 | 14.99 % | $ 929 K |  USA |
 |
Aziyo Biologics
AZYO
|
24.7 M | $ 1.48 | 1.37 % | $ 20.5 M | USA |
 |
Natus Medical Incorporated
NTUS
|
473 M | $ 31.08 | 1.94 % | $ 1.05 B | USA |
 |
Pulmonx Corporation
LUNG
|
83.8 M | $ 1.98 | 26.92 % | $ 77.4 M | USA |
 |
Medtronic PLC
MDT
|
33.5 B | $ 93.23 | -0.96 % | $ 120 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | $ 3.05 | -5.86 % | $ 30.6 M | USA |
 |
Cardiovascular Systems
CSII
|
236 M | $ 20.0 | 0.15 % | $ 844 M | USA |
 |
Neovasc
NVCN
|
2.55 M | $ 30.03 | - | $ 111 M |  Canada |
 |
Apollo Endosurgery
APEN
|
76.9 M | $ 10.0 | - | $ 475 M | USA |
 |
Titan Medical
TMDI
|
20.1 M | $ 0.14 | -26.32 % | $ 19.6 M | Canada |
 |
Viveve Medical
VIVE
|
6.43 M | $ 0.22 | -15.35 % | $ 1.71 M | USA |
 |
Invacare Corporation
IVC
|
181 M | $ 0.66 | - | $ 24.7 M | USA |
 |
Abiomed
ABMD
|
848 M | $ 381.02 | - | $ 17.2 B | USA |
 |
Allied Healthcare Products
AHPI
|
6.02 M | $ 0.55 | 3.58 % | $ 2.21 M | USA |
 |
Quanterix Corporation
QTRX
|
122 M | $ 5.48 | -3.52 % | $ 206 M | USA |
 |
AVITA Medical
RCEL
|
64.3 M | $ 3.66 | -3.43 % | $ 94.7 M |  Australia |
 |
CryoLife, Inc.
CRY
|
253 M | $ 17.84 | -4.14 % | $ 702 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
172 M | $ 24.04 | - | $ 1.77 B | USA |
 |
Sintx Technologies
SINT
|
2.63 M | $ 3.46 | -4.68 % | $ 12.9 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | $ 10.38 | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
41 M | $ 30.65 | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
62.5 M | $ 26.54 | - | $ 462 M | USA |
 |
ShockWave Medical
SWAV
|
730 M | $ 334.75 | - | $ 12.3 B | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
191 M | $ 7.16 | 0.28 % | $ 270 M | USA |
 |
ViewRay
VRAY
|
102 M | $ 2.64 | 1.54 % | $ 468 M | USA |
 |
Intersect ENT, Inc.
XENT
|
80.6 M | $ 28.24 | - | $ 955 M | USA |
 |
Bruker Corporation
BRKR
|
3.37 B | $ 38.72 | 0.21 % | $ 5.77 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
274 M | $ 70.98 | - | $ 3.31 B | USA |
 |
BIOLASE
BIOL
|
49.2 M | $ 0.13 | -13.19 % | $ 166 K | USA |
 |
Eargo
EAR
|
37.2 M | $ 2.57 | - | $ 10.2 M | USA |
 |
Delcath Systems
DCTH
|
37.2 M | $ 10.15 | 1.6 % | $ 289 M | USA |
 |
Viemed Healthcare
VMD
|
183 M | $ 6.86 | -1.29 % | $ 263 M | USA |
 |
SmileDirectClub
SDC
|
471 M | $ 0.08 | -53.45 % | $ 9.71 M | USA |
 |
Globus Medical
GMED
|
2.52 B | $ 62.75 | -0.77 % | $ 8.52 B | USA |
 |
ThermoGenesis Holdings
THMO
|
10.5 M | $ 0.31 | -25.84 % | $ 171 K | USA |
 |
Acutus Medical
AFIB
|
7.16 M | $ 0.09 | -26.83 % | $ 2.62 M | USA |
 |
ClearPoint Neuro
CLPT
|
31.4 M | $ 26.98 | 5.97 % | $ 729 M | USA |
 |
Surgalign Holdings
SRGA
|
82 M | $ 0.18 | -32.98 % | $ 1.68 M | USA |
 |
Conformis
CFMS
|
62 M | $ 2.27 | - | $ 16.4 M | USA |
 |
Sientra
SIEN
|
80.7 M | $ 0.18 | -16.59 % | $ 10.3 M | USA |
 |
NuVasive
NUVA
|
1.2 B | $ 39.75 | - | $ 2.07 B | USA |
 |
Cutera
CUTR
|
49.5 M | $ 0.1 | -10.19 % | $ 1.99 M | USA |
 |
Nemaura Medical
NMRD
|
77 K | $ 0.11 | -17.8 % | $ 2.74 M |  Britain |
 |
Vapotherm
VAPO
|
68.7 M | $ 1.27 | 6.72 % | $ 34 M | USA |
 |
Beyond Air
XAIR
|
3.7 M | $ 2.1 | 0.96 % | $ 142 M | USA |
 |
FONAR Corporation
FONR
|
97.6 M | $ 15.39 | 0.39 % | $ 101 M | USA |
 |
Talis Biomedical Corporation
TLIS
|
2.13 M | $ 4.38 | 3.55 % | $ 7.96 M | USA |